000166770 001__ 166770
000166770 005__ 20240229133529.0
000166770 0247_ $$2doi$$a10.3390/cancers13020230
000166770 0247_ $$2pmid$$apmid:33435218
000166770 0247_ $$2altmetric$$aaltmetric:97708824
000166770 037__ $$aDKFZ-2021-00109
000166770 041__ $$aeng
000166770 082__ $$a610
000166770 1001_ $$0P:(DE-He78)2fe44044f40217387daaf299f2eb7340$$aCosta, Barbara Maria$$b0$$eFirst author$$udkfz
000166770 245__ $$aA Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors.
000166770 260__ $$aBasel$$bMDPI$$c2021
000166770 3367_ $$2DRIVER$$aarticle
000166770 3367_ $$2DataCite$$aOutput Types/Journal article
000166770 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1698997564_23207
000166770 3367_ $$2BibTeX$$aARTICLE
000166770 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166770 3367_ $$00$$2EndNote$$aJournal Article
000166770 500__ $$aDKFZ-ZMBH Alliance#EA:A100#LA:A100# / HI-TRON
000166770 520__ $$aGlioblastomas (GBM) are the most aggressive tumors affecting the central nervous system in adults, causing death within, on average, 15 months after diagnosis. Immunocompetent in-vivo models that closely mirror human GBM are urgently needed for deciphering glioma biology and for the development of effective treatment options. The murine GBM cell lines currently available for engraftment in immunocompetent mice are not only exiguous but also inadequate in representing prominent characteristics of human GBM such as infiltrative behavior, necrotic areas, and pronounced tumor heterogeneity. Therefore, we generated a set of glioblastoma cell lines by repeated in vivo passaging of cells isolated from a neural stem cell-specific Pten/p53 double-knockout genetic mouse brain tumor model. Transcriptome and genome analyses of the cell lines revealed molecular heterogeneity comparable to that observed in human glioblastoma. Upon orthotopic transplantation into syngeneic hosts, they formed high-grade gliomas that faithfully recapitulated the histopathological features, invasiveness and immune cell infiltration characteristic of human glioblastoma. These features make our cell lines unique and useful tools to study multiple aspects of glioblastoma pathomechanism and to test novel treatments in an intact immune microenvironment.
000166770 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000166770 588__ $$aDataset connected to CrossRef, PubMed,
000166770 650_7 $$2Other$$aglioblastoma
000166770 650_7 $$2Other$$amouse model
000166770 650_7 $$2Other$$asyngeneic cell line
000166770 7001_ $$0P:(DE-He78)531cf6e04ba45b3c088cd4d4d3cc3c36$$aFletcher, Michael$$b1$$udkfz
000166770 7001_ $$0P:(DE-He78)843808e53ce583be326cf75564db3bdd$$aBoskovic, Pavle$$b2$$udkfz
000166770 7001_ $$0P:(DE-He78)64b69fa0317d5a02bd67528ceef097c2$$aIvanova, Ekaterina L$$b3$$udkfz
000166770 7001_ $$0P:(DE-He78)db396aa5e7017ae96520ba81ded5fc0e$$aEisemann, Tanja$$b4
000166770 7001_ $$0P:(DE-He78)d7efff917864e0e86459893cf0e83a99$$aLohr, Sabrina$$b5$$udkfz
000166770 7001_ $$0P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aBunse, Lukas$$b6$$udkfz
000166770 7001_ $$aLöwer, Martin$$b7
000166770 7001_ $$aBurchard, Stefanie$$b8
000166770 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b9$$udkfz
000166770 7001_ $$00000-0002-7633-4766$$aColtella, Nadia$$b10
000166770 7001_ $$aCusimano, Melania$$b11
000166770 7001_ $$aNaldini, Luigi$$b12
000166770 7001_ $$0P:(DE-He78)76aeb2431f7458c9261e69c5420390c6$$aLiu, Hai-Kun$$b13$$udkfz
000166770 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b14$$udkfz
000166770 7001_ $$0P:(DE-He78)d1939d434dd885fad08106329e3db719$$aRadlwimmer, Bernhard$$b15$$udkfz
000166770 7001_ $$0P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aAngel, Peter$$b16$$udkfz
000166770 7001_ $$0P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aPeterziel, Heike$$b17$$eLast author$$udkfz
000166770 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers13020230$$gVol. 13, no. 2, p. 230 -$$n2$$p230$$tCancers$$v13$$x2072-6694$$y2021
000166770 909CO $$ooai:inrepo02.dkfz.de:166770$$pVDB
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2fe44044f40217387daaf299f2eb7340$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)531cf6e04ba45b3c088cd4d4d3cc3c36$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)843808e53ce583be326cf75564db3bdd$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)64b69fa0317d5a02bd67528ceef097c2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)db396aa5e7017ae96520ba81ded5fc0e$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d7efff917864e0e86459893cf0e83a99$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)76aeb2431f7458c9261e69c5420390c6$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d1939d434dd885fad08106329e3db719$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000166770 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000166770 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000166770 9130_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000166770 9141_ $$y2021
000166770 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2018$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-11
000166770 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2018$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-11
000166770 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-11
000166770 9201_ $$0I:(DE-He78)A100-20160331$$kA100$$lA100 Signaltransduktion/ Wachstumskontrolle$$x0
000166770 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lB060 Molekulare Genetik$$x1
000166770 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x2
000166770 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x3
000166770 9201_ $$0I:(DE-He78)A240-20160331$$kA240$$lA240 Molekulare Neurogenetik$$x4
000166770 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x5
000166770 980__ $$ajournal
000166770 980__ $$aVDB
000166770 980__ $$aI:(DE-He78)A100-20160331
000166770 980__ $$aI:(DE-He78)B060-20160331
000166770 980__ $$aI:(DE-He78)D170-20160331
000166770 980__ $$aI:(DE-He78)B300-20160331
000166770 980__ $$aI:(DE-He78)A240-20160331
000166770 980__ $$aI:(DE-He78)HD01-20160331
000166770 980__ $$aUNRESTRICTED